A Doubly Caged Bis(salicylamide)-Based Anion Transporter for Phototriggered Breast Cancer Therapy.
Formulation of ion transporters, which hold great potential for anticancer therapy, as prodrugs/protransporters can overcome their nontarget activity, allowing for local activation using specified sti
APA
Roy NJ, Naorem R, et al. (2026). A Doubly Caged Bis(salicylamide)-Based Anion Transporter for Phototriggered Breast Cancer Therapy.. ACS omega, 11(12), 19894-19902. https://doi.org/10.1021/acsomega.6c01202
MLA
Roy NJ, et al.. "A Doubly Caged Bis(salicylamide)-Based Anion Transporter for Phototriggered Breast Cancer Therapy.." ACS omega, vol. 11, no. 12, 2026, pp. 19894-19902.
PMID
41939376
Abstract
Formulation of ion transporters, which hold great potential for anticancer therapy, as prodrugs/protransporters can overcome their nontarget activity, allowing for local activation using specified stimuli. Photocleavable protecting groups offer a robust strategy for caging transporter activity. Their reliance on light as a stimulus ensures ease of application and precise spatiotemporal control. Thus, there is a need to develop protransporters that are activatable in the biologically benign visible region of the electromagnetic spectrum. Herein, we report a series of bis-(salicylamide)-based anion antiporters caged with -nitrobenzyl groups to create protransporters that can be activated by 405 nm light. Active transporter release via two-step photocleavage and the subsequent photoinduced recovery of ion transport activity was verified. In vitro photoactivation of protransporters using 405 nm light efficiently induced cell death in MCF-7 and triple-negative MDA-MB-231 breast cancer cell lines.